ArticleCellular and molecular life sciences : CMLS2026
Clusterin elaborated by renal tubular epithelial cells under high oxalate stress serves as a matrix protein to facilitate kidney stone formation.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Calcium oxalate (CaOx) kidney stone is prevalent while the molecular mechanisms are not yet fully understood. The organic matrix of stones is rich in protein and has been considered to play a important role in stone aggregation and growth. Through multi-omics approaches, we identified that renal tubular epithelial cell (RTECs)-derived clusterin (CLU), as a matrix protein, promotes renal CaOx stone formation. Proteomics revealed significant enrichment of CLU in CaOx stones. Transcriptomic and single-cell transcriptome data from human kidney specimens confirmed marked upregulation of CLU in RTECs of kidney stone patients. In vitro, CLU accelerated renal CaOx crystal growth. Specifically, conditionally knock out of CLU in RTECs significantly alleviated CaOx crystal deposition in mouse kidneys. Furthermore, hyperoxaluria upregulated CLU in RTECs via the TGF-β1-SMAD2/3-Twist1 pathway, thereby facilitating stone formation. Our study highlights the role of the TWIST1-CLU regulatory axis in renal CaOx stone formation, suggesting CLU as a potential therapeutic target for CaOx kidney stones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.